Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

The trial enrolled more than 40,800 adults 50 and older from 11 countries.

The FDA has added new warnings to the Pfizer and Moderna COVID-19 vaccines about a rare heart condition that mostly affects young men.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...